78 related articles for article (PubMed ID: 20503407)
1. Targeted therapy in inflammatory breast cancer.
Yamauchi H; Ueno NT
Cancer; 2010 Jun; 116(11 Suppl):2758-9. PubMed ID: 20503407
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
Johnston S; Trudeau M; Kaufman B; Boussen H; Blackwell K; LoRusso P; Lombardi DP; Ben Ahmed S; Citrin DL; DeSilvio ML; Harris J; Westlund RE; Salazar V; Zaks TZ; Spector NL
J Clin Oncol; 2008 Mar; 26(7):1066-72. PubMed ID: 18212337
[TBL] [Abstract][Full Text] [Related]
3. Novel targeted therapies in inflammatory breast cancer.
Cristofanilli M
Cancer; 2010 Jun; 116(11 Suppl):2837-9. PubMed ID: 20503416
[TBL] [Abstract][Full Text] [Related]
4. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
Witters LM; Witkoski A; Planas-Silva MD; Berger M; Viallet J; Lipton A
Oncol Rep; 2007 Feb; 17(2):465-9. PubMed ID: 17203189
[TBL] [Abstract][Full Text] [Related]
5. Molecular targets for treatment of inflammatory breast cancer.
Yamauchi H; Cristofanilli M; Nakamura S; Hortobagyi GN; Ueno NT
Nat Rev Clin Oncol; 2009 Jul; 6(7):387-94. PubMed ID: 19468291
[TBL] [Abstract][Full Text] [Related]
6. Lapatinib-mediated cyclooxygenase-2 expression via epidermal growth factor receptor/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells.
Hsia TC; Tu CY; Chen YJ; Wei YL; Yu MC; Hsu SC; Tsai SL; Chen WS; Yeh MH; Yen CJ; Yu YL; Huang TC; Huang CY; Hung MC; Huang WC
Mol Pharmacol; 2013 Apr; 83(4):857-69. PubMed ID: 23355539
[TBL] [Abstract][Full Text] [Related]
7. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
[TBL] [Abstract][Full Text] [Related]
8. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
Tevaarwerk AJ; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
[TBL] [Abstract][Full Text] [Related]
9. EGFR and HER-2 antagonists in breast cancer.
O'Donovan N; Crown J
Anticancer Res; 2007; 27(3A):1285-94. PubMed ID: 17593621
[TBL] [Abstract][Full Text] [Related]
10. Systemic therapy of inflammatory breast cancer from high-dose chemotherapy to targeted therapies: the French experience.
Viens P; Tarpin C; Roche H; Bertucci F
Cancer; 2010 Jun; 116(11 Suppl):2829-36. PubMed ID: 20503415
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory breast cancer: novel preoperative therapies.
Overmoyer BA
Clin Breast Cancer; 2010 Feb; 10(1):27-32. PubMed ID: 20133255
[TBL] [Abstract][Full Text] [Related]
12. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
13. Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin.
Dragowska WH; Verreault M; Yapp DT; Warburton C; Edwards L; Ramsay EC; Huxham LA; Minchinton AI; Gelmon K; Bally MB
Breast Cancer Res Treat; 2007 Dec; 106(3):319-31. PubMed ID: 17347776
[TBL] [Abstract][Full Text] [Related]
14. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'.
Charafe-Jauffret E; Tarpin C; Bardou VJ; Bertucci F; Ginestier C; Braud AC; Puig B; Geneix J; Hassoun J; Birnbaum D; Jacquemier J; Viens P
J Pathol; 2004 Mar; 202(3):265-73. PubMed ID: 14991891
[TBL] [Abstract][Full Text] [Related]
15. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.
Fuchs BC; Fujii T; Dorfman JD; Goodwin JM; Zhu AX; Lanuti M; Tanabe KK
Cancer Res; 2008 Apr; 68(7):2391-9. PubMed ID: 18381447
[TBL] [Abstract][Full Text] [Related]
16. ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective.
Saxena R; Dwivedi A
Med Res Rev; 2012 Jan; 32(1):166-215. PubMed ID: 22183797
[TBL] [Abstract][Full Text] [Related]
17. Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast.
Chan KC; Knox WF; Gee JM; Morris J; Nicholson RI; Potten CS; Bundred NJ
Cancer Res; 2002 Jan; 62(1):122-8. PubMed ID: 11782368
[TBL] [Abstract][Full Text] [Related]
18. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
19. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.
Lai CJ; Bao R; Tao X; Wang J; Atoyan R; Qu H; Wang DG; Yin L; Samson M; Forrester J; Zifcak B; Xu GX; DellaRocca S; Zhai HX; Cai X; Munger WE; Keegan M; Pepicelli CV; Qian C
Cancer Res; 2010 May; 70(9):3647-56. PubMed ID: 20388807
[TBL] [Abstract][Full Text] [Related]
20. Persistent E-cadherin expression in inflammatory breast cancer.
Kleer CG; van Golen KL; Braun T; Merajver SD
Mod Pathol; 2001 May; 14(5):458-64. PubMed ID: 11353057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
